Aakaar Medical Technologies IPO day 1: GMP, subscription status, price band, other details of NSE SME IPO

Aakaar Medical Technologies IPO: The initial public offering (IPO) of medical aesthetic company Aakaar Medical Technologies opened for subscription on Friday, June 20. The ₹ 25.64 crore book building issue is entirely a fresh issue of 35.62 lakh shares. On the first day of subscription, the NSE SME IPO saw a tepid response from retail investors.
By 4 PM on Friday, the first day of subscription, the issue had been subscribed to 31 per cent, with the retail portion subscribed to 25 per cent, the segment reserved for non-institutional investors (NIIs) subscribed to 39 per cent, and the segment reserved for qualified institutional buyers subscribed to 33 per cent.
1. Aakaar Medical Technologies IPO GMP: According to market sources, the latest grey market premium (GMP) of Aakaar Medical Technologies shares was nil. This means the stock could list at par with the issue price.
2. Aakaar Medical Technologies IPO date: The SME IPO opened for subscription on Friday, June 20, and will conclude on Tuesday, June 24.
3. Aakaar Medical Technologies IPO price: The price band of the public issue has been fixed at ₹ 68 to ₹ 72 per equity share.
4. Aakaar Medical Technologies IPO size: The company intends to raise ₹ 25.64 crore from the issue, which it will use to fund working capital requirements and for general corporate purposes.
5. Aakaar Medical Technologies IPO lot size: Bidders can apply in lots, and one lot of the NSE SME IPO comprises 1,600 company shares.
6. Aakaar Medical Technologies IPO reservation: As much as 47 per cent of the net issue is reserved for QIBs, while 33 per cent of the net issue is reserved for retail investors, and a little over 14 per cent of the issue is reserved for NIIs.
7. Aakaar Medical Technologies IPO allotment date: The IPO is closing on Tuesday, June 24, so as per SEBI's listing rules, the company is expected to finalise the share allotment on Wednesday, June 25. Successful bidders can expect shares of the company in their demat accounts on Thursday, June 26, and bidders who fail to get the allocation may get a refund on the same day.
8. Aakaar Medical Technologies IPO book-running lead manager and registrar: Indorient Financial Services Limited is the book-running lead manager, while Bigshare Services Private Limited is the registrar for the issue.
9. Aakaar Medical Technologies IPO listing: As per SEBI's T+3 rule of IPO listing, the SME IPO is proposed for listing on the NSE SME on Friday, June 27.
10. Aakaar Medical Technologies business overview: According to the company's RHP, Aakaar Medical Technologies is a medical aesthetic company dealing in a wide range of aesthetics and specialised cosmetic products and devices.
The company's profit after tax (PAT) for FY23 stood at ₹ 2.15 crore, which rose to ₹ 2.87 crore in FY24 and ₹ 6.04 crore in FY25.
Revenue from operations for FY23, FY24 and FY25 stood at ₹ 32.78 crore, ₹ 46.11 crore and ₹ 61.58 crore, respectively.
Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions, as market conditions can change rapidly, and circumstances may vary.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Hans India

42 minutes ago

• Hans India

HDB sets IPO price band at Rs 700-740

New Delhi: HDB Financial Services, a subsidiary of HDFC Bank, on Friday fixed a price band of Rs 700-740 per share for its Rs 12,500 crore company is expected to list on the BSE and NSE on July 2. At the upper end of the price band, the company is valued at nearly Rs 61,400 crore. HDB Financial Services' maiden public issue will open for subscription on June 25 and conclude on June 27, while the bidding for the anchor investor will open for a day on June 24, the company announced. The IPO is a combination of a fresh issue of equity shares worth Rs 2,500 crore and an Offer For Sale (OFS) of Rs 10,000 crore by promoter HDFC Bank. At present, HDFC Bank holds a 94.36 per cent stake in HDB Financial Services, a non-banking financial company (NBFC) arm of the bank. The company proposes to utilise the proceeds from the fresh issue to strengthen its Tier-I capital base. This will support future capital needs, including additional lending, to support business growth. The decision to list HDB Financial Services follows the Reserve Bank of India's mandate in October 2022, requiring NBFCs in the upper layer to list on the stock exchanges within three years. Last year, HDFC Bank's board approved a share sale worth Rs 12,500 crore, comprising Rs 10,000 crore OFS related to HDB Financial Services. After the proposed IPO, HDB Financial Services will continue to be a subsidiary of the bank, in compliance with the provisions of the applicable regulations. Half of the issue size has been reserved for qualified institutional buyers, 35 per cent for retail investors and the remaining 15 per cent for non-institutional investors.

News18

7 hours ago

• News18

Influx Healthtech IPO Receives Over 201.3x Subscription On Final Day Of Bidding; Check GMP Today

The GMP of the Influx Healthtech IPO is 18.75%, indicating strong listing gains for investors. Influx Healthtech IPO Day 3: The initial public offering of Influx Healthtech Ltd has been closed today, Friday, June 20. The IPO has received a strong response from investors. Till 5:00 pm on the final day of bidding on Friday, the Rs 55.63-crore SME IPO received an overwhelming 201.35 times subscription, garnering bids for 81,71,71,200 shares as against 40,58,400 shares on offer. The retail and NII participation stood at 117.68 times and 481.10 times, respectively. Its qualified institutional buyer (QIB) category got a 137.87 times subscription. The three-day IPO was opened on Wednesday, June 18. It received a 5.89 times subscription on Day 1 on Wednesday and a 25.47 times subscription on Day 2. Influx Healthtech IPO Price The price of the Influx Healthtech IPO has been fixed at Rs 96 apiece. Influx Healthtech IPO Lot Size The minimum lot size is 1,200 shares, requiring a retail investment of Rs 1,15,200. For NIIs, the minimum is 2 lots (2,400 shares) at Rs 2,30,400. According to market observers, the GMP of the Influx Healthtech IPO is 18.75%, indicating strong listing gains for investors. The 18.75% GMP is significantly lower than the 39.58% premium recording in the morning. The GMP is based on market sentiments and keeps changing. 'Grey market premium' indicates investors' readiness to pay more than the issue price. The shares of Influx Healthtech Ltd will be listed on the NSE SME on June 25. The Eppeltone Engineers IPO is a book-built issue worth Rs 55.63 crore, comprising a fresh issue of 46.94 lakh equity shares worth Rs 45.07 crore and an offer for sale of 11 lakh shares aggregating to Rs 10.56 crore. The IPO opened for subscription on June 18, 2025, and will close on June 20, 2025. Share allotment is likely to be finalised on June 23, with the listing expected on the NSE SME platform on June 25, 2025. The price band is set at Rs 96 per share. Influx Healthtech Ltd's revenue increased 5% and its profit after tax (PAT) rose 19% between the financial year ending with March 31, 2025, and March 31, 2024. Rarever Financial Advisors Pvt Ltd is the book-running lead manager of the Influx Healthtech IPO, while Maashitla Securities Private Limited is the registrar for the issue. The market maker for Influx Healthtech IPO is R K Stock Holding Private Limited. Influx Healthtech Ltd, founded in September 2020, is a healthcare-focused CDMO with three manufacturing units in Thane, producing tablets, capsules, powders, liquid orals, and softgels.

Time of India

8 hours ago

• Time of India

Stricter regulations lead to drop in derivatives participation: NSE chief

Ahmedabad: With stricter regulations in place, there has been a significant drop in participation in the derivatives segment, said Ashish Chauhan, MD & CEO of the National Stock Exchange (NSE), on Friday. Chauhan was in the city to launch a book based on his life. He also participated in a discussion on Indian financial markets with international tax expert Mukesh Patel. Speaking to the media, Chauhan said, "SEBI increased lot sizes and margin requirements for trading in derivatives to ensure that small investors do not lose money. In June last year, around 55 lakh investors traded in derivatives at least once. That number has now come down to about 30 lakh." He also stated that NSE International Exchange at GIFT City has signed an agreement with the Cyprus Stock Exchange for dual listing and joint product development.